CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018
|
|
- Earl Summers
- 5 years ago
- Views:
Transcription
1 CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update November 17 th, 2018
2 Faculty/Presenter Disclosure Faculty: Rick Ward Relationships with commercial interests: Grants/Research Support: Pfizer, Lilly, Cortria Corp Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Eli Lilly, Forest, Janssen, Leo Pharmaceuticals, Novartis, Merck, Pfizer, Sanofi Aventis, Schering-Plough, Shire Consulting Fees: Astra Zeneca, BI, Shire, Pfizer, BMS Other: Nil
3 Faculty/Presenter Disclosure Faculty: Jean Grégoire Relationships with commercial interests: Grants/Research Support: Amarin Speakers Bureau/Honoraria and Consulting Fees: Amgen, AstraZeneca, Bayer, Boehringer-ingelheim, Bristol-Myers- Squibb, HTS Therapeutics, Jannsen, Merck, Novartis, Novonordisk, Pfizer, Sanofi, Servier, Sunovion, Valeant Former Co-chair Canadian Lipid Guideline
4 Disclosure of Commercial Support This program has NOT received financial support from any commercial sources. The Canadian Cardiovascular Society is supporting travel and expenses for the speakers.
5 Mitigating Potential Bias The information presented is based on recent information that is explicitly evidence-based and is solely based on Canadian Cardiovascular Society Guidelines.
6 Following this program, participants will: 1. Utilize the CCS Dyslipidemia Guidelines and recent evidence to guide the identification and management of patients with lipid disorders with a focus on the elderly and patients with hereditary lipid disorders 2. Incorporate a strategy for patients who are statin intolerant 3. Describe the evidence and indications for the use of new therapies to treat high risk patients with lipid disorders 4. Identify the target of therapy for patients where medical therapy is indicated
7 Case 1 statin use in the elderly A healthy, active 77 year old man presents for annual health review. He has a history of hypertension and asks about his cholesterol. His LDL is 4.1 mmol/l. His calculated Framingham Risk Score puts him into the High Risk category.
8 Case 1 - DP Would you have screened him in the first place?
9 Who to Screen
10 How to Screen RECOMMENDATIONS We recommend non-fasting lipid and lipoprotein testing which can be performed in adults in whom screening is indicated as part of a comprehensive risk assessment to reduce CVD events (Strong Recommendation, High Quality Evidence). We suggest that for individuals with a history of triglyceride levels >4.5 mmol/l that lipid and lipoprotein levels be measured fasting (Conditional Recommendation, Low Quality Evidence). Practical tip: Compared to fasting lipid values, there will be minimal change with non-hdl-c, a slight decrease in LDL-C and small increase in triglyceride concentrations when individuals do not fast.
11 Benefits of Non-fasting Lipids Patient convenience no need to go to lab early in the morning and fasting; no need for retesting if not fasting Reduced wait times and reduced early morning patient burden in clinical laboratories Safety prevention of hypoglycemic episodes in diabetics Enhances compliance and avoids delay in lipid screening and follow up tests Enhanced predictive value for CVD and mortality of nonfasting lipids Identification of high remnants/insulin resistance Removal of need to perform fasting blood work generally HbA1c is accepted as a diagnostic test and follow up test by CDA and ADA that does NOT have to be accompanied by a fasting glucose High fasting glucose usually results in HbA1c test
12 2016 Recommendations We recommend that a cardiovascular risk assessment be completed every 3 to 5 years for men and women age 40 to 75. A risk assessment may also be completed whenever a patient s expected risk status changes. Options include using the 10 Year Risk (Framingham Model) or Cardiovascular Age (Cardiovascular Life Expectancy Model). The results should be shared with the patient to support shared decision making and improve the likelihood that they will reach lipid targets. (Strong Recommendation, High Quality Evidence)
13 What would you recommend? 1. Ignore and continue a healthy lifestyle 2. Start on a low dose statin 3. Treat to a target of LDL of < 2.0 Mmol/L 4. Order a stress test or other investigations 5. Omega 3 fatty acid supplementation
14 When to Consider Pharmacological Treatment in Risk Management RECOMMENDATIONS Statin indicated conditions: We recommend management that includes statin therapy in high risk conditions including clinical atherosclerosis, abdominal aortic aneurysm, most diabetes mellitus, chronic kidney disease (age >50 years) and those with LDL-C 5.0 mmol/l to lower the risk of CVD events and mortality (Strong Recommendation, High Quality Evidence). Primary prevention: a) We recommend management that does not include statin therapy for individuals at low risk (modified FRS < 10 %) to lower the risk of CVD events (Strong Recommendation, High Quality Evidence). b) We recommend management that includes statin therapy for individuals at high risk (modified FRS 20%) to lower the risk of CVD events (Strong Recommendation, High Quality Evidence). c) We recommend management that includes statin therapy for individuals at intermediate risk (IR; modified FRS 10-19%) with LDL-C 3.5 mmol/l to lower the risk of CVD events. Statin therapy should also be considered for IR persons with LDL-C <3.5 mmol/l but with apo B 1.2 g/l or non-hdl-c 4.3 mmol/l or in men 50 and women 60 years of age with 1 CV risk factor (Strong Recommendation, High Quality Evidence). Values and preferences - This recommendation applies to individuals with an LDL-C 1.8 mmol/l. Any decision regarding pharmacological therapy for CV risk reduction in IR persons needs to include a thorough discussion of risks, benefits, and cost of treatment, alternative nonpharmacological methods for CV risk reduction and each individual s preference. The proportional risk reduction associated with statin therapy in RCTs in (IR) persons is of similar magnitude to that attained in highrisk persons. Moreover, irreversible severe side effects are very rare and availability of generic statins results in low cost of therapy. However, the absolute risk reduction is lower. Statin therapy may be considered in persons with FRS of 5%-9% with LDL-C 3.5 mmol/l or other CV risk factors as the proportional benefit from statin therapy will be similar in this group as well.
15 10 yrs Risk vs Lifetime Risk 70 Men (n = 3564) Women (n = 4362) Adjusted cumulative incidence of CVD (%) Attained age (years) Major RFs 1 Major RF 1 Elevated RF 1 Not optimal RF All optimal RFs Lloyd-Jones DM et al. Circulation 2006; 113: Anderson TJ, et al. Canadian Cardiovascular Society Guidelines for the management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult, Canadian Journal of Cardiology (2016), doi: / j.cjca
16
17 RRs of MI and Stroke NNT 83 NNT 142
18 RRs of All-Cause Death and CV Death
19 Recommendations for Primary Prevention With Statins in Apparently Healthy People Mortensen MB, Falk E. et al. Jam Coll Cardiolo 2017;71:85-94.
20 What if.. 1. The patient also had well controlled T2DM? 2. The patient was already on a statin for a uncomplicated MI he suffered when he was 67? 3. The patient had been on a statin for primary prevention for the past 5 years?
21 Case 2 Statin intolerance A 62 year old overweight and inactive lawyer with hypertension and T2DM is a patient in your practice who presented to the ED with moderate sized STEMI. He comes to your office shortly after discharge complaining of side effects from pills. Since he has been home, he has noted generalized muscle pain. He googled this and is certain it is the high dose statin on which he was discharged. You review blood work done 9 months prior to his MI.* * He cancelled numerous appoints with you and your dietician to review
22 Case 2 Statin Intolerance T chol 5.59 TG 7.19 HDL.81 LDL Unable to calculate Non-HDL 4.78 HbA1c 7.5
23 Do you think the statin is causing his pain?
24 What would you recommend? 1. Stop Statin, monitor myalgia and rechallenge. 2. Reduce to lowest tolerated dose. 3. Since major issue is TG s and HDL start on fibrate. 4. Change to niacin, bile acid sequestrant, Ezetimibe or PCSK9 Inhibitor. 5. Tell him to ride it out that the pain will improve over time.
25 Principles of Management of Statin Intolerance Is there an indication for statin therapy? Does the patient have features limiting or precluding use of statins? Is the patient fully aware of the indication for statin treatment, intended benefits and safety of statins, and properly counselled to avoid nocebo effects*? Have dietary, weight and exercise goals been included in the therapeutic plan? Have supplements used to avoid myalgia while taking statins been discouraged? Has systematic challenge/de-challenge/re-challenge occurred and failed to result in achievement of therapeutic goal? If needed, which non-statin agent is likely to help achieve therapeutic goal with or without dual therapy to avoid polypharmacy? *Nocebo effects; perceived adverse reactions experienced by a patient who receives a placebo. Mancini GB et al. Can J Cardiol 2016 Jul;32(7 Suppl):S35-65.
26 What if our patient truly was statin intolerant and very high risk? 1. Ezetimibe? 2. Bile Acid Sequestrant? 3. PCSK9 Inhibitor?
27 Statin based Options for LDL-Cholesterol Lowering in Statin Intolerant Patient Lower statin dose Switch to alternative statin Altered dosing regimens Rosuvastatin mg 3 x weekly or alternate days Rosuvastatin 5-20 mg once weekly Low dose / alternative statin /alternating day rosuvastatin + Ezetimibe and/or Bile acid binding resin PCSK9 inhibitor
28 RECOMMENDATIONS Non-Statin Therapy We recommend ezetimibe as second-line therapy to lower LDL-C in patients with clinical cardiovascular disease if targets are not reached on maximally tolerated statin therapy (Strong Recommendation, High Quality Evidence). We recommend that niacin not be added to statin therapy for CVD prevention in patients who have achieved LDL-C targets (Strong Recommendation, High Quality Evidence). Values and preferences - It remains unclear whether niacin offers CV benefits in other patient groups, such as those with LDL-C above target or those with low HDL-C or high TG. We recommend that fibrates not be added to statin therapy for CVD event prevention in patients who have achieved LDL-C targets (Strong Recommendation, High Quality Evidence). Values and preferences - In sub-group analysis, patients with elevated triglycerides and low HDL-C may benefit from fibrate therapy. Anderson TJ, Gregoire J, Pearson GJ et al., Can J Cardiol 2016 (In-Press). DOI: /j.cjca
29 Non-Statin Therapy RECOMMENDATIONS We suggest that bile acid sequestrants be considered for LDL-C lowering in high risk patients who remain above target despite statin +/- ezetimibe therapy (Conditional Recommendation, Low Quality Evidence). We suggest the use of PCSK9 inhibitors (evolocumab, alirocumab) to lower LDL-C for patients with heterozygous familial hypercholesterolemia whose LDL-C remains above target despite maximally tolerated statin therapy (Conditional Recommendation, Moderate Quality Evidence). We suggest that Evolocumab be added to background therapy in patients with homozygous familial hypercholesterolemia and continued if LDL-C lowering is documented (Conditional Recommendation, Moderate Quality Evidence). We suggest that PCSK9 inhibitors be considered to lower LDL-C for patients with atherosclerotic cardiovascular disease in those not at LDL-C goal despite maximally tolerated statin +/- ezetimibe therapy (Conditional Recommendation, Moderate Quality Evidence). Values and preferences - Definitive outcome trials with PCSK9 inhibitors are underway but have not yet been completed. However, phase 3 efficacy trials show consistent reduction in LDL-C and reassuring trends towards reduced CV events, even though not powered for such. Given the very high lifetime risk faced by patients with FH or ASCVD, clinicians should balance the anticipated benefits of robust LDL C lowering with PCSK9 inhibitors against the lack of definitive outcomes data. We suggest lomitapide and mipomersen* may be considered exclusively in patients with homozygous familial hypercholesterolemia (Conditional Recommendation, Moderate Quality Evidence). *not approved in Canada Anderson TJ, Gregoire J, Pearson GJ et al., Can J Cardiol 2016 (In-Press). DOI: /j.cjca
30 Case 3 Familial Hypercholesterolemia A 40 year old patient comes in for a periodic health review. His father recently died from complications of MS but you are reminded he had an MI in his 50 s with long standing hypertension and dyslipidemia. Our patient is asymptomatic, normotensive, somewhat active with a BMI of 27 The only abnormalities of his blood work are his lipid profile.
31 Cholesterol Panel - CT : mmol/l - TG : 2.20 mmol/l - LDL: 8.72 mmol/l - HDL: 1.58 mmol/l - Non-HDL: 9.77 mmol/l Other Lab Values - LFT: Normal - Creatinine: 82 umol/l - TSH: 2.4 mui/l - Glycemia: 5.3 mmol/l - HBA1C: 0.052% - No proteinuria.
32 Does he have FH?
33 HeFH Diagnostic Information Canadian criteria for HeFH Definite clinical familial hypercholesterolemia Imputed baseline / untreated LDL-C 8.5 mmol/l Tendinous xanthomata Premature ASCVD Family history of premature CVD (1 male relative <55 yo) Simon Broome Register criteria for HeFH Definite diagnosis for clinical familial hypercholesterolemia Imputed baseline / untreated LDL-C >4.9 mmol/l Tendinous xanthomata Family history of premature CVD (1 male relative <55 yo) Dutch Lipid Clinic Network criteria for HeFH Definite clinical familial hypercholesterolemia Imputed baseline / untreated LDL-C 8.5 mmol/l Premature coronary artery disease Tendinous xanthomata Family history of premature CVD (1 male relative <55 yo)
34
35 Canadian definition for the clinical diagnosis of familial hypercholesterolemia
36 Case 3 1. Would you treat? 2. How would you treat? 3. What is your target?
37 Cumulative event-free survival (%) CHD Free Survival Among Individuals with FH according to Statin Treatment Kaplan Meier curve estimates of cumulative CHD-free survival among individuals with familial hypercholesterolemia according to statin treatment (P < for difference) Statin treatment No statin treatment Follow-up (years) Nordestgaard B G et al. Eur Heart J 2013;34(45): a.
38 You confirmed the diagnosis of FH. What would be your initial lipid lowering therapy? 1) Lifestyle modifications for 3 months. 2) Atorvastatin 20 mg daily. 3) Atorvastatin 80 mg daily. 4) Lifestyle modifications and Atorvastatin 80 mg daily
39 Pharmacological Treatment Indications & Targets Category Consider Initiating pharmacotherapy if: Target NNT Primary Prevention High (FRS 20%) Intermediate (FRS 10-19%) LDL-C <2.0 mmol/l or >50% LDL-C 3.5 mmol/l or Non-HDL-C 4.3 mmol/l or Apo B 1.2 g/l or Men 50 & women 60 yrs and 1 CV risk factor Or Apo B <0.8 g/l Statin Indicated Conditions** Clinical atherosclerosis* (CAD, CVD, PAD) Or 20 Abdominal aortic aneurysm Diabetes mellitus: 40 yrs, or >15 yrs duration & age 30 yrs (DM 1), or microvascular disease non-hdl-c <2.6 mmol/l CKD (age 50 yrs): egfr < 60 ml/min/1.73 m 2, or ACR >3 mg/mmol LDL-C 5.0 mmol/l >50% in LDL-C * consider LDL-C < 1.8 mmol/l for subjects with ACS within last 3 months;** statins indicated as initial therapy
40 After 3 months on Atorvastatin 80 mg daily, LDL-C is 4.54 mmol/l. What will be your next step? 1) No change 2) Switch to Rosuvastatin 40 mg/day 3) Add Ezetimibe 10 mg to Atorvastatin 80 mg/day 4) Add a PCSK9 inhibitor
41 After 3 months on Atorvastatin 80 mg daily and Ezetimibe 10 mg daily, LDL-C is 3.2 mmol/l. Are you satisfied with the result? 1) Yes 2) No
42 What if our patient had a history of ASCVD and the LDL-C on treatment with Atorvastatin 80 and Ezetimibe is 3.2 mmol/l? 1) No change 2) Add Colesevelam to Atorvastatin 80 mg/day and Ezetimibe 10 mg/day 3) Add a PCSK9 inhibitor
43 Evolocumab: RUTHERFORD-2 Add-on to Statins: Significant LDL-C Lowering with Monthly or Bi-weekly Placebo wk10&12 EvoMab wk10&12 % Change from Baseline in LDL-C % 1% Q2W 61% 61% +2% +5% QM 64% 56% Placebo wk12 EvoMab wk12 HeFH Study (N = 331) HeFH patients unable to achieve an LDL-C < 2.6 mmol/l despite statin therapy with or without ezetimibe ~ 60%LDL lowering in this difficult patient group Reflexive LDL-C measurements; Co-primary Endpoints: Mean % change from baseline in LDL at week 10/12 and at Week 12 Adapted from Robinson JG, et al. JAMA. 2014;311(18): (LAPLACE-2); Raal F, et al. Lancet. 2015;385(9965):
44 LS mean (SE) % change from baseline to Week 24 Alirocumab: ODYSSEY FH I and FH II Alirocumab Significantly Reduced LDL-C from Baseline to Week 24 versus Placebo Primary Endpoint: Percent Change from Baseline to Week 24 in LDL-C All patients on background max-tolerated statin ±other lipid-lowering therapy FH I 9.1% FH II 2.8% Alirocumab Placebo -10 N=322 N=163 N=166 N= % had dose increase at W % had dose increase at W LS mean difference (SE) vs. placebo: -48.8% -48.7% 57.9% (2.7) P< % (3.4) P< KasteleinJ.P John et al. European Heart Journal. 2015;36(43): ODYSSEY FH I & II)
45 The LDL-C on Atorvastatin 80 plus Ezetimibe 10 and Evolocumab 140 is now at 1.12 mmol/l What else do you need to do now? Cascade screening
46 QUESTIONS?
Contemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationDYSLIPIDEMIA. Michael Brändle, Stefan Bilz
DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationDeep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City
Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationChallenges in lipid management
Challenges in lipid management Milan Gupta MD, FRCPC, FACC State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University of Toronto
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.
Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ) Following
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationWhats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i?
Whats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationEVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378
Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior
More informationSECONDARY PREVENTION OF CORONARY HEART DISEASE AND ISCHAEMIC STROKE/TIA
PRIMARY PREVENTION OF CHD AND STROKE IN HIGH RISK PATIENTS Random non fasting test for total cholesterol, HDL cholesterol (TC:HDL ratio) and LFTs If cholesterol > 7.5 mmol/l or LDL C 5mmol/l exclude secondary
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationFamilial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationEfficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study
Efficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study Erik Stroes, 1 John Guyton, 2 Michel Farnier, 3 Norman Lepor, 4 Fernando Civeira,
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationS3-13: Lipids: Looking forward to
S3-13: Lipids: Looking forward to 2018 Heart and Stroke Clinical Update 1010-1140 9 Dec 2017 Robert Hegele MD, FRCPC, FACP Distinguished University Professor Endocrinologist, University Hospital Western
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationPCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?
PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials? Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationClinical Dyslipidemia. Tom Ransom April 5, 2018
Clinical Dyslipidemia Tom Ransom April 5, 2018 Disclosures Faculty/Presenter: Tom Ransom Relationships with commercial interests: Grants/research support: Research trials: Principal/Sub Investigator, CDHA,
More informationGuidelines on Lowering LDL-C Levels
Scientific Insights Into LDL-C, PCSK9, and CV Risks High circulating LDL-C levels are associated with increased risk for ASCVD 1,2 Statin drugs interfere with cholesterol production, lowering serum LDL-C
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationDefining and Controlling Severe Familial Hypercholesterolemia
Defining and Controlling Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD InCor-University of Sao Paulo Hospital Israelita Albert Einstein Brazil 1 Disclosure Honoraria received for consulting,
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More information